Expert Review of Endocrinology & Metabolism最新文献

筛选
英文 中文
Treatment of type 2 diabetes patients with heart conditions. 治疗伴有心脏病的2型糖尿病患者。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-05-01 DOI: 10.1080/17446651.2023.2204941
Gulali Aktas, Burcin Meryem Atak Tel, Ramiz Tel, Buse Balci
{"title":"Treatment of type 2 diabetes patients with heart conditions.","authors":"Gulali Aktas,&nbsp;Burcin Meryem Atak Tel,&nbsp;Ramiz Tel,&nbsp;Buse Balci","doi":"10.1080/17446651.2023.2204941","DOIUrl":"https://doi.org/10.1080/17446651.2023.2204941","url":null,"abstract":"<p><strong>Introduction: </strong>While type 2 diabetes mellitus (T2DM) increases the risk of cardiac complications, diabetes treatment choices may increase or decrease the rates of cardiac events. In the present review, we comprehensively discussed the treatment options of diabetic subjects with cardiac conditions.</p><p><strong>Areas covered: </strong>Current evidence related to diabetes treatment in cardiac situations has been reviewed. Clinical trials and meta-analyses on cardiac safety of anti-diabetic medicines are discussed. Treatment choices with proven benefits and those at least without associated increased cardiac risk were drawn from clinical trials; meta-analyses and cardiac safety studies in the recent medical literature were the basis of the suggestions in the present review.</p><p><strong>Expert opinion: </strong>We can suggest that hypoglycemia and extreme hyperglycemia should be avoided in acute ischemic heart conditions. Certain diabetic treatment options, especially sodium-glucose cotransporter-2 (SGLT2) inhibitors, can reduce overall cardiovascular mortality and hospitalization due to heart failure. Therefore, we suggest that physicians should choose SGLT2 inhibitors as the first-line treatment option in diabetic patients with heart failure or those who have a high risk of heart failure development. T2DM increases the risk of atrial fibrillation (AF), and metformin and pioglitazone seem to reduce the risk of AF in diabetic population.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 3","pages":"255-265"},"PeriodicalIF":3.2,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9399139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Current management of diabetes patients with COVID-19. 目前使用 COVID-19 对糖尿病患者进行管理。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-08 DOI: 10.1080/17446651.2023.2187375
Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
{"title":"Current management of diabetes patients with COVID-19.","authors":"Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma","doi":"10.1080/17446651.2023.2187375","DOIUrl":"10.1080/17446651.2023.2187375","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus (DM) and the 2019 coronavirus (COVID-19) appear to interact in both directions. There is mounting proof that patients with DM have a worse COVID-19 prognosis than those without it. Pharmacotherapy is also known to affect in view of the possible interplay between drugs and the pathophysiology of the above conditions in a given patient.</p><p><strong>Areas covered: </strong>In this review, we discuss the pathogenesis of COVID-19 and its connections with diabetes mellitus. We also analyze the treatment modalities for COVID-19 and diabetes patients. The possible mechanisms of the different medications and their management limitations are also systematically reviewed.</p><p><strong>Expert opinion: </strong>COVID-19 management as well as its knowledge base is changing constantly. The Pharmacotherapy and the choice of drugs also need to be specifically considered in view of the concomitant presence of these conditions in a patient. Anti-diabetic agents must be carefully evaluated in diabetic patients in view of the disease's severity, blood glucose level, appropriate treatment, and other components that could aggravate adverse events. A methodical technique is anticipated to enable the safe and rational use of drug therapy in COVID-19-positive diabetic patients to take.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-9"},"PeriodicalIF":3.2,"publicationDate":"2023-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9075994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant publications in diabetes pharmacotherapy and technology in 2020 2020年糖尿病药物治疗和技术方面的重要出版物
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-06 DOI: 10.1080/17446651.2023.2187618
Jennifer N. Clements, Rachel Franks, Diana Isaacs, Kevin Malloy, Lisa T. Meade, Sara (Mandy) Reece, Debra J. Reid, Eileen D. Ward
{"title":"Significant publications in diabetes pharmacotherapy and technology in 2020","authors":"Jennifer N. Clements, Rachel Franks, Diana Isaacs, Kevin Malloy, Lisa T. Meade, Sara (Mandy) Reece, Debra J. Reid, Eileen D. Ward","doi":"10.1080/17446651.2023.2187618","DOIUrl":"https://doi.org/10.1080/17446651.2023.2187618","url":null,"abstract":"Introduction The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are summarized.Areas covered Members of the Association of Diabetes Care and Education Specialists Pharmacy Community of Interest were selected to review articles published in prominent peer-reviewed journals in 2020 that most impacted diabetes pharmacotherapy and technology. A list of 37 nominated articles were compiled (22 in diabetes pharmacotherapy and 15 in diabetes technology). Based on discussion among the authors, the articles were ranked based on significant contribution, impact, and diversity to diabetes pharmacotherapy and technology. The top 10 highest ranked publications (n=6 for diabetes pharmacotherapy and n=4 in diabetes technology) are summarized in this article.Expert opinion With the significant number of publications in diabetes care and education, it can be challenging and overwhelming to remain current with published literature. This review article may be helpful in identifying key articles in diabetes pharmacotherapy and technology from the year 2020.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135036388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Notice of duplicate publication: Significant publications in diabetes pharmacotherapy and technology in 2020. 重复出版通知:2020 年糖尿病药物治疗和技术领域的重要出版物。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 Epub Date: 2023-03-31 DOI: 10.1080/17446651.2023.2195265
{"title":"Notice of duplicate publication: Significant publications in diabetes pharmacotherapy and technology in 2020.","authors":"","doi":"10.1080/17446651.2023.2195265","DOIUrl":"10.1080/17446651.2023.2195265","url":null,"abstract":"","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"ii"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9264174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Notice of duplicate publication: Current management of diabetes patients with COVID-19. 重复出版通知:COVID-19对糖尿病患者的管理现状。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 Epub Date: 2023-03-31 DOI: 10.1080/17446651.2023.2195269
{"title":"Notice of duplicate publication: Current management of diabetes patients with COVID-19.","authors":"","doi":"10.1080/17446651.2023.2195269","DOIUrl":"10.1080/17446651.2023.2195269","url":null,"abstract":"","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"i"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9264175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current management of diabetes patients with COVID-19. 目前使用 COVID-19 对糖尿病患者进行管理。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 Epub Date: 2023-03-07 DOI: 10.1080/17446651.2023.2187215
Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma
{"title":"Current management of diabetes patients with COVID-19.","authors":"Arup Kumar Misra, Gaurav Rangari, Madhavrao C, Sushil Sharma","doi":"10.1080/17446651.2023.2187215","DOIUrl":"10.1080/17446651.2023.2187215","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetes mellitus (DM) and the 2019 coronavirus (COVID-19) appear to interact in both directions. There is mounting proof that patients with DM have a worse COVID-19 prognosis than those without it. Pharmacotherapy is also known to affect in view of the possible interplay between drugs and the pathophysiology of the above conditions in a given patient.</p><p><strong>Areas covered: </strong>In this review, we discuss the pathogenesis of COVID-19 and its connections with diabetes mellitus. We also analyze the treatment modalities for COVID-19 and diabetes patients. The possible mechanisms of the different medications and their management limitations are also systematically reviewed.</p><p><strong>Expert opinion: </strong>COVID-19 management as well as its knowledge base is changing constantly. The Pharmacotherapy and the choice of drugs also need to be specifically considered in view of the concomitant presence of these conditions in a patient. Anti-diabetic agents must be carefully evaluated in diabetic patients in view of the disease's severity, blood glucose level, appropriate treatment, and other components that could aggravate adverse events. A methodical technique is anticipated to enable the safe and rational use of drug therapy in COVID-19-positive diabetic patients to take.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"199-207"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effects of alcohol on testosterone synthesis in men: a review. 酒精对男性睾酮合成的影响:综述
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 DOI: 10.1080/17446651.2023.2184797
Stephen James Smith, Adrian Leo Lopresti, Timothy John Fairchild
{"title":"The effects of alcohol on testosterone synthesis in men: a review.","authors":"Stephen James Smith,&nbsp;Adrian Leo Lopresti,&nbsp;Timothy John Fairchild","doi":"10.1080/17446651.2023.2184797","DOIUrl":"https://doi.org/10.1080/17446651.2023.2184797","url":null,"abstract":"<p><strong>Introduction: </strong>Testosterone concentrations in men decline with advancing age, with low testosterone concentrations being associated with multiple morbidities, an increased risk of early mortality, and a reduced quality of life. The purpose of this study was to examine the effects of alcohol on testosterone synthesis in men by investigating its effects on each level of the hypothalamic-pituitary-gonadal axis.</p><p><strong>Areas covered: </strong>Acute consumption of a low-to-moderate amount of alcohol increases testosterone concentrations in men, while consumption of a large volume of alcohol is associated with a reduction in serum testosterone concentrations. Elevated testosterone concentrations result from the increased activity of detoxification enzymes in the liver. Conversely, the primary mechanisms of action involved in the reduction of testosterone are increased hypothalamic-pituitary-adrenal axis activity, inflammation, and oxidative stress. When alcohol is consumed in excess, particularly chronically, it negatively affects testosterone production in men.</p><p><strong>Expert opinion: </strong>Since testosterone is an important component of men's health and wellbeing, current levels of alcohol consumption in many countries of the world require urgent attention. Elucidating the relationship between alcohol consumption and testosterone may be useful in identifying strategies to attenuate the testosterone-reducing effects of excessive or chronic alcohol consumption.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"155-166"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9291539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
COVID-19 and diabetes mellitus: a review of the incidence, pathophysiology and management of diabetes during the pandemic. 2019冠状病毒病与糖尿病:大流行期间糖尿病的发病率、病理生理和管理综述
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 DOI: 10.1080/17446651.2023.2176300
Jordana Faruqi, Ashok Balasubramanyam
{"title":"COVID-19 and diabetes mellitus: a review of the incidence, pathophysiology and management of diabetes during the pandemic.","authors":"Jordana Faruqi,&nbsp;Ashok Balasubramanyam","doi":"10.1080/17446651.2023.2176300","DOIUrl":"https://doi.org/10.1080/17446651.2023.2176300","url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic has changed the landscape of modern medicine on a global scale. An emerging concern is the recognition of a bidirectional relationship between COVID-19 and diabetes. Diabetes is a risk factor for severe COVID-19 illness. Intriguingly, recent epidemiological and <i>in vitro</i> studies suggest that infection with SARS-CoV-2, the causative viral agent of COVID-19, is associated with new-onset diabetes and worsening diabetes control. These factors have affected the management of diabetes.</p><p><strong>Areas covered: </strong>This review provides an overview of our current understanding of the incidence and prevalence of diabetes in relation to the COVID-19 pandemic, highlights studies evaluating SARS-CoV-2's beta cell tropism and its effects on insulin secretion and sensitivity and evaluates the impact of the pandemic on diabetes management and metabolic control.</p><p><strong>Expert opinion: </strong>Epidemiological studies have noted an increase in the incidence of new-onset diabetes associated with COVID-19 in patients with phenotypes of type 1 diabetes, type 2 diabetes and Ketosis-Prone Diabetes. Prospective studies are needed to fully elucidate the association between COVID-19 and diabetes and to characterize persons at risk of developing diabetes after SARS-CoV-2 infection, identify those who should be screened for diabetes, and determine the natural histories of different forms of diabetes associated with COVID-19.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"167-179"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9292320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
HDACs as an emerging target in endocrine tumors: a comprehensive review. hdac作为内分泌肿瘤的新靶点:综述
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 DOI: 10.1080/17446651.2023.2183840
Eckhard Klieser, Bettina Neumayer, Pietro Di Fazio, Christian Mayr, Daniel Neureiter, Tobias Kiesslich
{"title":"HDACs as an emerging target in endocrine tumors: a comprehensive review.","authors":"Eckhard Klieser,&nbsp;Bettina Neumayer,&nbsp;Pietro Di Fazio,&nbsp;Christian Mayr,&nbsp;Daniel Neureiter,&nbsp;Tobias Kiesslich","doi":"10.1080/17446651.2023.2183840","DOIUrl":"https://doi.org/10.1080/17446651.2023.2183840","url":null,"abstract":"<p><strong>Introduction: </strong>The pathogenic role of deregulated histone (de-)acetylation by histone deacetyles (HDACs) has been demonstrated in several human cancers. While some HDAC inhibitors (HDACi) have been approved for individual entities, for endocrine tumors such translation into clinical practice has not yet been achieved.</p><p><strong>Areas covered: </strong>Relevant results identified by structured searches in PubMed as well as in reference lists are summarized in a narrative review to discuss the current knowledge of HDAC involvement and their therapeutic relevance in endocrine tumors. For thyroid, neuroendocrine, and adrenal tumors, various oncogenic mechanisms of HDAC deregulation and effects of HDAC inhibitors (HDACi) have been identified in preclinical studies including direct cancer cell toxicity and modification of differentiation status.</p><p><strong>Expert opinion: </strong>Based on positive pre-clinical results, the research on HDAC (inhibition) in the various endocrine tumors should be intensified - yet, it needs to be considered that i) HDACs' oncogenic actions might constitute only a part of epigenetic mechanisms driving cancer, ii) individual HDAC has different roles in different endocrine tumor entities, iii) inhibition of HDACs might be especially attractive in combination with conventional or other targeted therapies, and iv) new HDAC-inhibiting drugs with improved specificity or functionally modified HDACi might further improve their efficacy.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"143-154"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9285524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Significant publications in diabetes pharmacotherapy and technology in 2020. 2020 年在糖尿病药物治疗和技术方面发表重要著作。
IF 3.2
Expert Review of Endocrinology & Metabolism Pub Date : 2023-03-01 Epub Date: 2023-03-07 DOI: 10.1080/17446651.2023.2187779
Jennifer N Clements, Rachel Franks, Diana Isaacs, Kevin Malloy, Lisa T Meade, Sara Mandy Reece, Debra J Reid, Eileen D Ward
{"title":"Significant publications in diabetes pharmacotherapy and technology in 2020.","authors":"Jennifer N Clements, Rachel Franks, Diana Isaacs, Kevin Malloy, Lisa T Meade, Sara Mandy Reece, Debra J Reid, Eileen D Ward","doi":"10.1080/17446651.2023.2187779","DOIUrl":"10.1080/17446651.2023.2187779","url":null,"abstract":"<p><strong>Introduction: </strong>The most significant articles on diabetes pharmacotherapy and technology in the peer-reviewed literature from 2020, as determined by a panel of pharmacists with expertise in diabetes care and education, are summarized.</p><p><strong>Areas covered: </strong>Members of the Association of Diabetes Care and Education Specialists Pharmacy Community of Interest were selected to review articles published in prominent peer-reviewed journals in 2020 that most impacted diabetes pharmacotherapy and technology. A list of 37 nominated articles were compiled (22 in diabetes pharmacotherapy and 15 in diabetes technology). Based on discussion among the authors, the articles were ranked based on significant contribution, impact, and diversity to diabetes pharmacotherapy and technology. The top 10 highest ranked publications (n = 6 for diabetes pharmacotherapy and n = 4 in diabetes technology) are summarized in this article.</p><p><strong>Expert opinion: </strong>With the significant number of publications in diabetes care and education, it can be challenging and overwhelming to remain current with published literature. This review article may be helpful in identifying key articles in diabetes pharmacotherapy and technology from the year 2020.</p>","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":"18 2","pages":"131-142"},"PeriodicalIF":3.2,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9661306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信